To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors

NCT02977065 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemias

Interventions

DRUG: Atorvastatin 20mg
DRUG: Atorvastatin 20 mg + CKD-519 50 mg
DRUG: Atorvastatin 20 mg + CKD-519 100 mg
DRUG: Atorvastatin 20 mg + CKD-519 200 mg
DRUG: Rosuvastatin 10 mg
DRUG: Rosuvastatin 10 mg + CKD-519 100 mg

Sponsor

Chong Kun Dang Pharmaceutical